Antipneumococcal activity of ceftobiprole, a novel broad-spectrum cephalosporin.
about
Ceftobiprole for the treatment of pneumonia: a European perspectiveCeftobiprole medocaril in the treatment of hospital-acquired pneumoniaNewer antibacterial drugs for a new century.Intensive therapy with ceftobiprole medocaril of experimental foreign-body infection by methicillin-resistant Staphylococcus aureusCeftobiprole medocaril: a review of its use in patients with hospital- or community-acquired pneumonia.Single- and multistep resistance selection studies on the activity of retapamulin compared to other agents against Staphylococcus aureus and Streptococcus pyogenes.Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.Emerging agents to combat complicated and resistant infections: focus on ceftobiproleProbability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects.The antimicrobial armamentarium: evaluating current and future treatment options.Clonal spread of highly beta-lactam-resistant Streptococcus pneumoniae isolates in Taiwan.Anti-MRSA beta-lactams in development, with a focus on ceftobiprole: the first anti-MRSA beta-lactam to demonstrate clinical efficacy.Ceftobiprole: an extended-spectrum anti-methicillin-resistant Staphylococcus aureus cephalosporin.Ceftobiprole: first cephalosporin with activity against methicillin-resistant Staphylococcus aureus.Ceftobiprole: a new broad spectrum cephalosporin.Ceftobiprole: a new cephalosporin for the treatment of skin and skin structure infections.Emerging drugs for pneumococcal pneumonia.Pharmacokinetic and pharmacodynamics evaluation of ceftobiprole medocaril for the treatment of hospital-acquired pneumonia.Recent advances in antibacterial drugs.β-lactams against emerging 'superbugs': progress and pitfalls.In vitro antibacterial activity of NB-003 against Propionibacterium acnes.Postantibiotic effect of ceftobiprole against 12 Gram-positive organismsEvaluation of ceftobiprole activity against a variety of gram-negative pathogens, including Escherichia coli, Haemophilus influenzae (β-lactamase positive and β-lactamase negative), and Klebsiella pneumoniae, in a rabbit meningitis model.Activities of ceftobiprole and other beta-lactams against Streptococcus pneumoniae clinical isolates from the United States with defined substitutions in penicillin-binding proteins PBP 1a, PBP 2b, and PBP 2x.Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin.Activities of ceftobiprole, a novel broad-spectrum cephalosporin, against Haemophilus influenzae and Moraxella catarrhalis.Multistep resistance development studies of ceftaroline in gram-positive and -negative bacteria.Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agentsIn silico study on Penicillin derivatives and Cephalosporins for upper respiratory tract bacterial pathogens.
P2860
Q26796463-430C2543-8B21-4D80-9EA5-F436ECFC442AQ28085517-C21446A5-2AB1-42A5-B6B4-05F10F7CAF87Q30433333-47791808-F647-4BAE-A874-047C83267590Q33935282-A21E5963-E240-4D45-B542-2B0146341D1EQ34433342-FC4EE863-E7FB-4295-A83C-7B33A3EA472FQ34564481-897120E1-5A68-443F-9BE4-FFD2672B7CD4Q34624359-326D0DAE-9D01-43F1-B223-258DE650D457Q35026567-E0B5F065-8DCC-4643-A3A0-6A6E736A32D3Q35879080-06246C1F-8DB8-42FA-B26E-927B183C6EB3Q36264494-9BE01ABB-C697-4AD2-9FFB-4F1122B5DE0BQ36702928-1D220858-96CC-43A8-ACBA-A372019D42E2Q36763997-6C5F97F2-964F-44C5-8F6D-B6F75ECFAB08Q37162872-171D8F3B-2CB7-4E47-AA41-1C8CCFFECCECQ37461413-D2C9258D-02B7-47D1-86F2-DDDA8AE0228EQ37519733-9D96058D-CA08-4D72-B72D-5749F7259D52Q37593094-A8CB8CFC-C314-4CE3-92B9-07496D4E83F4Q37864327-BDB270D7-8F2E-42AE-BDE6-865579E5A9CBQ38099393-FEEA468E-0C69-486C-ADE9-3CE92F35D1F2Q38115306-46E4F29B-9FAD-49FC-AD90-1D7EF4B63519Q38177344-0A5E5618-255B-49FC-86D3-4CD100A47237Q38283280-22926B9F-AE86-4721-9768-B1D3880B5EDAQ39077719-E74160D2-AD04-45CC-A862-FA620575E1F3Q40600643-1BB9C01D-BC4E-4F6F-BEDB-5506FF0E60F7Q41473443-6F918FDC-C014-478C-9A21-2D1D43FC1DFBQ41847350-81C5EAA2-82C8-4CD2-A8A5-ECA16E0B1A7FQ41849670-5EF4A52C-C812-42BE-8B35-522334251E99Q42111061-00494ABE-488F-40D0-8FBA-0ECF3D958A53Q42112427-E6D0A30D-F3E1-42C3-8F44-730A91A95559Q55443184-CA59006A-769C-42B6-B000-EF1CAC1D4D72
P2860
Antipneumococcal activity of ceftobiprole, a novel broad-spectrum cephalosporin.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Antipneumococcal activity of ceftobiprole, a novel broad-spectrum cephalosporin.
@en
Antipneumococcal activity of ceftobiprole, a novel broad-spectrum cephalosporin.
@nl
type
label
Antipneumococcal activity of ceftobiprole, a novel broad-spectrum cephalosporin.
@en
Antipneumococcal activity of ceftobiprole, a novel broad-spectrum cephalosporin.
@nl
prefLabel
Antipneumococcal activity of ceftobiprole, a novel broad-spectrum cephalosporin.
@en
Antipneumococcal activity of ceftobiprole, a novel broad-spectrum cephalosporin.
@nl
P2093
P2860
P1476
Antipneumococcal activity of ceftobiprole, a novel broad-spectrum cephalosporin.
@en
P2093
Bonifacio Dewasse
Bülent Bozdogan
Catherine Clark
Dianne B Hoellman
Gengrong Lin
Kim Credito
Klaudia Kosowska
Pamela McGhee
Peter C Appelbaum
Stuart Shapiro
P2860
P304
P356
10.1128/AAC.49.5.1932-1942.2005
P407
P577
2005-05-01T00:00:00Z